Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MG-7 antigen-pulsed autologous dendritic cell vaccine (Second Hospital of Shandong University)
- Development stage
- Unknown
- Lead developer
- Second Hospital of Shandong University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
This is an autologous dendritic cell (DC) vaccine loaded with the MG-7 antigen, a tumor-associated antigen specifically expressed in gastric cancer cells. Developed by The Second Hospital of Shandong University, the vaccine is produced by transfecting a patient's own dendritic cells with a lentiviral vector encoding the MG-7 antigen. Once administered, these modified DCs present the MG-7 antigen to the immune system, activating cytotoxic T lymphocytes (CTLs) to specifically target and eliminate gastric cancer cells expressing MG-7. It is currently being evaluated in Phase I/II clinical trials for the treatment of advanced gastric cancer, both as a monotherapy and in combination with CTLs or the PD-1 inhibitor sintilimab.
- Other names
- MG-7 DC vaccineMG7 DC vaccineMG 7 DC vaccineMG-7 antigen-pulsed autologous DC vaccineMG7 antigen-pulsed autologous DC vaccineMG 7 antigen-pulsed autologous DC vaccineDendritic Cell vaccine-The Second Hospital of Shandong University-gastric cancer
02
Targets
NeuGcGM3 (N-glycolyl-GM3 ganglioside)
Beyond the preview
Go deeper on MG-7 antigen-pulsed autologous dendritic cell vaccine (Second Hospital of Shandong University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MG-7 antigen-pulsed autologous dendritic cell vaccine (Second Hospital of Shandong University).